Uterine Fibroid Market Overview
The global Uterine Fibroid market was valued at USD 2.1 billion in 2024 and is expected to grow from USD 2.3 billion in 2025 to USD 4.5 billion by 2035, registering a CAGR of 7.1% during the forecast period from 2026 to 2035. Increasing awareness of uterine fibroid treatments, the rising prevalence of fibroids, advancements in diagnostic technologies, and growing demand for minimally invasive treatment options are supporting market expansion.
North America held a leading position in the market, valued at USD 900 million in 2024 and projected to reach USD 1.7 billion by 2035. Among fibroid types, intramural fibroids represented a significant segment, valued at USD 900 million in 2024 and expected to reach USD 1.75 billion by 2035. The increasing adoption of minimally invasive procedures, innovative pharmacological therapies, and advanced imaging technologies is further strengthening market growth.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/reports/uterine-fibroid-market
Key Companies in the Uterine Fibroid Market
Medtronic
Johnson & Johnson
Abbott Laboratories
CeloNova BioSciences
Merit Medical Systems
Hologic
Siemens Healthineers
GE Healthcare
Stryker
Thermo Fisher Scientific
Boston Scientific
Olympus Corporation
The market is being driven by growing awareness of women’s health issues and the increasing prevalence of uterine fibroids among women of reproductive age. Patients are increasingly seeking treatments that offer shorter recovery times and lower hospitalization requirements, supporting the adoption of minimally invasive procedures and non-surgical approaches. Advancements in pharmacological therapies, imaging technologies, uterine artery embolization, and focused ultrasound treatments are also creating new opportunities for market participants.
The Uterine Fibroid Market is segmented by type, diagnosis method, treatment method, end user, and region. Fibroid types include intramural fibroids, subserosal fibroids, submucosal fibroids, and pedunculated fibroids. Diagnosis methods include ultrasound, magnetic resonance imaging, hysterosalpingography, and computed tomography. Treatment methods cover medication, surgery, uterine artery embolization, and focused ultrasound surgery, while end users include hospitals, diagnostic centers, specialty clinics, and research institutions.
Recent Developments and Market Trends:
Medtronic announced a strategic partnership in March 2025 to enhance access to embolization-based treatments for uterine fibroids.
Hologic announced a next-generation MRI-guided focused ultrasound platform in June 2025 in collaboration with Siemens Healthineers.
Merit Medical Systems announced the acquisition of a specialist embolization microsphere producer in February 2025 to expand its uterine fibroid embolization portfolio.
Minimally invasive and non-surgical treatment options are gaining traction as patients increasingly seek alternatives with shorter recovery periods.
Advanced imaging technologies, including MRI and ultrasound, are becoming increasingly important for accurate diagnosis and treatment planning.
Reasons to Buy the Report:
Understand the current market size, growth trajectory, and forecast of the global Uterine Fibroid Market through 2035.
Analyze key market segments based on fibroid type, diagnosis method, treatment method, and end user.
Evaluate regional opportunities across North America, Europe, Asia Pacific, South America, and the Middle East and Africa.
Identify major companies and assess their competitive positioning in the uterine fibroid treatment landscape.
Understand the impact of minimally invasive therapies, advanced imaging, pharmacological innovations, and embolization techniques.
Assess emerging opportunities associated with patient awareness, telemedicine, specialized women’s healthcare services, and research investments.
Future Outlook:
The global Uterine Fibroid Market is expected to experience strong growth through 2035 as awareness of fibroid diagnosis and treatment continues to increase. Rising demand for minimally invasive and non-surgical therapies, improvements in diagnostic imaging, expanding healthcare access, and continued investment in women’s health are expected to support market expansion. The growing adoption of uterine artery embolization, focused ultrasound, personalized treatment approaches, and telemedicine services is likely to create additional opportunities for market participants.
➤➤Explore Our Latest Related Reports:
